BIONTECH SE SPON. ADRS 1/ US09075V1026 /
2024-05-22 9:19:37 PM | Chg. +10.50 | Volume | Bid2024-05-22 | Ask2024-05-22 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
94.40EUR | +12.51% | 148 Turnover: 12,756.95 |
-Bid Size: - | -Ask Size: - | -EUR | - | 2.24 |
GlobeNewswire
05-21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
05-17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
04-22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
04-07
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
03-20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
03-20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
03-11
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
03-06
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire
02-08
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
01-31
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire
01-22
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire
01-09
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-21
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire
2023-12-18
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire
2023-11-06
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
2023-10-26
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...